Renal resistive indices may independently predict disease progression and mortality in CKD patients

Written By :  Aditi
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-12-04 01:30 GMT   |   Update On 2023-12-04 05:04 GMT

Chronic kidney disease is a significant global public health issue, affecting at least one in ten adults. Factors like obesity, hypertension, and diabetes contribute to its rising prevalence. Determining prognostic markers for CKD and assessing their independent association with outcomes remains challenging. Kidney ultrasound is the gold standard imaging technique for ruling out urinary...

Login or Register to read the full article

Chronic kidney disease is a significant global public health issue, affecting at least one in ten adults. Factors like obesity, hypertension, and diabetes contribute to its rising prevalence. Determining prognostic markers for CKD and assessing their independent association with outcomes remains challenging. Kidney ultrasound is the gold standard imaging technique for ruling out urinary tract obstruction, assessing kidney size, and evaluating corticomedullary differentiation.

A recent study published in BMC Nephrology led by Dr Chloe Kharsa and colleagues has concluded that those with elevated Renal resistive indices (RRI) ≥ 0.7 are at a higher risk of mortality following adjustment to medications and lifestyle modifications. According to this study, It can be considered an independent prognostic factor in CKD patients.

RRI predict kidney disease progression. The present study evaluated the association of RRI with mortality and dialysis initiation after adjustment to therapeutic and lifestyle interventions.

This retrospective study analyzed data from CKD patients who were followed for at least two years in three nephrology clinics ( between 2006 and 2019). These patients had a recorded RRI level. The Kaplan Meier and log-rank tests compared survival between normal and high RRI patients. Cox regression analysis assessed the relationship between RRI and death or dialysis after adjustments.

Key findings from the study are:

  • One hundred ninety-two patients were analyzed with a mean age of 66 years, with 78% males.
  • 68 patients had RRI < 0.7 and 124 had RRI ≥ 0.7.
  • There was a negative correlation between baseline eGFR and RRI.
  • The survival was significantly better in patients with RRI < 0.7 with a Log Rank test < 0.001.
  • There was a significant association between RRI and mortality with HR of 1.08 based on univariate Cox regression analysis that remained significant following adjustment to cardiovascular risk factors and interventions. This included salt reduction, BP control, statins and RAAS inhibitors.
  • According to Cox regression analysis, there was a significant association between RRI and dialysis initiation with HR = 1.06.

They said, "Our study revealed that mortality risk is higher in patients with an elevated RRI ≥ 0.7 after adjustment to medications and lifestyle modifications. "

According to our results, an increase of 0.01 in RRI increases the death by 7% after a mean follow-up of 73 months. They added that this association is sustained after adjustment to cardiovascular risk factors, kidney function, ACR, and therapeutic and lifestyle interventions.

The study's limitations include a retrospective nature, absence of Doppler US after implementation of treatment and lifestyle modifications, bias in patient selection, and the definition of compliance to salt reduction not being homogenous in all cases.

Reference:

Kharsa, C., Beaini, C., Chelala, D. et al. Association of renal resistive indices with kidney disease progression and mortality. BMC Nephrol 24, 348 (2023). https://doi.org/10.1186/s12882-023-03398-6


Tags:    
Article Source : BMC Nephrology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News